This study used network pharmacology methods to identify potential targets of BSHXHZF for treating WD liver fibrosis, including tanshinone IIA, quercetin, flavonoids, α-amyrin, and hesperidin, as well as signaling pathways, such as IL-17, HIF-1, prolactin, and NF-κB. This evidence concerns the gene IL17A and Hepatic fibrosis.